An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis

Autor: Harvey W. Smith, Alison Hirukawa, Virginie Sanguin-Gendreau, Ipshita Nandi, Catherine R. Dufour, Dongmei Zuo, Kristofferson Tandoc, Matthew Leibovitch, Salendra Singh, Jonathan P. Rennhack, Matthew Swiatnicki, Cynthia Lavoie, Vasilios Papavasiliou, Carolin Temps, Neil O. Carragher, Asier Unciti-Broceta, Paul Savage, Mark Basik, Vincent van Hoef, Ola Larsson, Caroline L. Cooper, Ana Cristina Vargas Calderon, Jane Beith, Ewan Millar, Christina Selinger, Vincent Giguère, Morag Park, Lyndsay N. Harris, Vinay Varadan, Eran R. Andrechek, Sandra A. O’Toole, Ivan Topisirovic, William J. Muller

Publikováno v: Nature Communications, Vol 10, Iss 1, Pp 1-19 (2019)

Polycomb Repressor Complex 2 (PRC2) is frequently up-regulated in cancers. Here, the authors show that the tyrosine kinase c-Src stimulates mitochondrial function to signal energy sufficiency to mTORC1, increasing translation of the PRC2 subunits EZH

Externí odkaz: https://doaj.org/article/4b4ac9959bb3404bb739e2634c53409f

Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability

Autor: Asier Unciti-Broceta, Neil O. Carragher, Valerie G. Brunton, Bin-Zhi Qian, Margaret C. Frame, Mark J. Arends, Maria Lopalco, Christina Schoenherr, Henry Beetham, Craig Fraser, Juan R. Luque-Ortega, Rafael Contreras-Montoya, Alison F. Munro, Teresa Valero, Kenneth G. Macleod, Morwenna Muir, John C. Dawson, Xue-Feng Li, Emily R. Webb, Daniel Lietha, Carolin Temps

Supplementary Data from A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f536ea2ccfc4256e470e9896ed6057b
https://doi.org/10.1158/0008-5472.22428648.v1

Supplementary Figure from Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors

Autor: Valerie G. Brunton, Adam Byron, Andrew H. Sims, Asier Unciti-Broceta, Morwenna Muir, Jayne Culley, Carolin Temps, David A. Parry, Alexander E.P. Loftus, Olga Murina, Billie G.C. Griffith, Henry Beetham

Supplementary Figure from Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ac2321e4c5ebd700f7f961f6fc0ceef
https://doi.org/10.1158/0008-5472.22430041.v1

Abstract 4031: In vivo studies demonstrate differences in target inhibition and anticancer efficacy between NXP900 and dasatinib in ovarian clear cell carcinoma model

Autor: Saúl Navarro-Marchal, Carolin Temps, Iñigo Lanzagorta-Calvillo, John C. Dawson, Enrique Poradosu, Neil O. Carragher, Valerie G. Brunton, Asier Unciti-Broceta

Publikováno v: Cancer Research. 83:4031-4031

Background: NXP900 (formerly known as eCF506) is a novel SRC/YES1 family kinase (SFK) inhibitor that locks SRC into its native closed conformation (= type 1.5), thereby inhibiting both kinase activity and complex formation with protein partners inclu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3139772a1acc5e11bad95ba8dffd94e0
https://doi.org/10.1158/1538-7445.am2023-4031

Loss of Integrin-linked kinase sensitizes breast cancer to SRC inhibitors

Autor: Henry Beetham, Billie G.C. Griffith, Olga Murina, Alexander E.P. Loftus, David A. Parry, Carolin Temps, Jayne Culley, Morwenna Muir, Asier Unciti-Broceta, Andrew H. Sims, Adam Byron, Valerie G. Brunton

Publikováno v: Beetham, H, Griffith, B, Murina, O, Loftus, A, Parry, D A, Temps, C, Culley, J, Muir, M, Unciti-Broceta, A, Sims, A H, Byron, A & Brunton, V G 2021, ' Loss of Integrin-linked kinase sensitizes breast cancer to SRC inhibitors ', Cancer Research . https://doi.org/10.1158/0008-5472.CAN-21-0373
Beetham, H, Griffith, B G C, Murina, O, Loftus, A E P, Parry, D A, Temps, C, Culley, J, Muir, M, Unciti-Broceta, A, Sims, A H, Byron, A & Brunton, V G 2022, ' Loss of Integrin-linked kinase sensitizes breast cancer to SRC inhibitors ', Cancer Research, vol. 82, no. 4, pp. 632-647 . https://doi.org/10.1158/0008-5472.CAN-21-0373

SRC is a nonreceptor tyrosine kinase with key roles in breast cancer development and progression. Despite this, SRC tyrosine kinase inhibitors have so far failed to live up to their promise in clinical trials, with poor overall response rates. We aim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e60490b72d4b6e9896c2cb3f20e716f6
https://www.pure.ed.ac.uk/ws/files/245549967/Loss_of_Integrin_linked_kinase_sensitizes_breast_cancer_to_SRC_inhibitors_published_AAM.pdf